BRD4 and renal cell carcinoma: Western blotting assay results in primary “RCC-1” cells confirmed that PI3K-AKT-mTORC1 activation (Figure 4C) and BRD4-dependent proteins (Bcl-2/Myc, Figure 4D) were both significantly downregulated following SF2523 (1 μM) treatment.